CF Pharmtech (02652) signs strategic cooperation with JD Health

CF PHARMTECH (02652) announced that on March 20, 2026, the company officially signed a strategic cooperation agreement with JD HEALTH Limited (JD HEALTH). According to the strategic cooperation agreement, JD HEALTH will serve as the exclusive online platform for the first release of multiple heavyweight new products in the respiratory and nasal fields by the company for the next three years. The main contents of the cooperation include: (i) JD HEALTH will provide online first sales and patient service support for the company's new products using its online platform and supply chain service capabilities; (ii) JD HEALTH will assist the company in enhancing the commercial efficiency of new products by leveraging its capabilities in prescription acceptance and patient management; and (iii) the two parties will explore a chronic disease management cooperation model based on internet healthcare. This cooperation aims to fully leverage the respective advantages of both parties in the areas of innovative drug research and development and digital medical supply chain, and jointly promote the rapid popularization of high-quality respiratory system treatment solutions, allowing patients to enjoy more convenient and standardized medication and chronic disease management services. The company has long been dedicated to research and production in the respiratory and nasal fields, continuously advancing the research and development and upgrading of innovative drugs based on its globally competitive technology platform in the inhalation formulation field. It has built a product pipeline covering diseases such as allergic rhinitis, chronic sinusitis, asthma, and chronic obstructive pulmonary disease, forming a comprehensive management system covering single and compound drugs, all age groups, and the entire disease cycle. By delivering small molecule drugs, small nucleic acid drugs, and other molecular drugs through the inhalation route, the company explores a better balance between efficacy and safety based on its mechanism of action at the cellular and genetic levels, marking a key progress in the company's transformation from complex formulations to innovative drugs at the source. This model not only expands the treatment field to severe diseases such as respiratory and central nervous system diseases with global clinical needs that are inadequately met, but also optimizes immune regulatory effects through local drug delivery strategies, forming a synergistic innovative path of "inhalation local delivery + cell-targeted delivery + gene/protein regulation." Given the large patient base and long-term management characteristics of the above-mentioned diseases in China, the Board of Directors believes that entering into a strategic cooperation agreement is in the overall interest of the company and its shareholders. This cooperation is expected to enhance the accessibility of the company's products to patients and improve the commercial efficiency of new products.